Market research
ATXS Astria Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 23 Apr 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 718M
- P/E ratio
- Not available
- Analyst target
- 13
- Dividend yield
- Not available
- Beta
- 0.02
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 718M
- P/E ratio
- Not available
- Analyst target
- 13
- Dividend yield
- Not available
- Beta
- 0.02
About
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
Research context
Astria Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the ATXS discussion.
No comments yet
Start a focused discussion about ATXS.